摘要
目的观察瑞舒伐他汀对持续性心房纤颤(房颤)患者血清超敏C反应蛋白(hs-CRP)、白介素6(IL-6)、同型半胱氨酸(Hcy)水平的影响以及在复律中的作用。方法 338例持续性房颤患者按复律是否成功分为A组(复律成功组,n=217)和B组(复律不成功,n=121),A组按是否使用瑞舒伐他汀分为对照组(103例)和治疗组(114例)。治疗组与对照组在随访终点按是否复发房颤分为两亚组:窦性心律维持组与房颤复发组。分别于当天和随访终点抽静脉血5ml,测定血清hs-CRP、IL-6、Hcy水平。比较组间水平差异及随访房颤转复后窦性心律维持情况。结果 A组与B组hs-CRP、IL-6及Hcy水平比较,差异有统计学意义(P<0.05)。治疗前治疗组与对照组hs-CRP、IL-6及Hcy水平比较,差异无统计学意义(P>0.05);治疗后治疗组上述指标明显低于对照组,差异有统计学意义(P<0.05)。治疗组窦性心律维持率为56.8%(n=63),对照组窦性心律维持率为40.4%(n=40),两组比较差异有统计学意义(P=0.018)。治疗组和对照组亚组间比较:房颤组较窦性心律组hs-CRP、IL-6、Hcy水平增高,差异有统计学意义(P<0.05)。结论瑞舒伐他汀可能通过抗炎、抑制氧化应激反应、改善心肌纤维化作用来降低患者血清hs-CRP、IL-6、Hcy水平,从而减少房颤的发生与复发。
Objective To observe the effect of rosuvastatin on persistent atrial fibrillation（AF） hypersensitivity in patients with serum C reactive protein（hs-CRP）,interleukin 6（IL-6）,homocysteine（Hcy） concentration and the role in cardioversion.Methods According to whether successful cardioversion the use of rosuvastatin,338 patients with persistent atrial fibrillation were divided into successful cardioversion group（A group,n=217） and failure cardioversion group（B group,n=121）.Then according to whether the use of rosuvastatin,the patients of A group were divided into the control group（103 cases） and the treatment group（114 cases）.According to whether the recurrence of atrial fibrillation,the treatment group and the control group were divided into two subgroups：the sinus rhythm group and the recurrence group in the end of follow-up.On the day of admission and study endpoints,collect the venous blood 5ml of all patients,detect serum hs-CRP,IL-6,Hcy concentration.Compare serum hs-CRP,IL-6,Hcy concentration between A group and B group,the control group and the treatment group,and the two subgroups and follow up sinus rhythm maintenance of patients after cardioversion.Results Comparition of hs-CRP,IL-6 and Hcy concentration between A group and B group,the difference was statistically significant（P〈0.01）.Before treatment,the treatment group compared with the control group,hs-CRP,IL-6 and Hcy concentration,the difference was no significant（P〈0.05）;these indicators were significantly lower than the control group after treatment,the difference was statistically significant（P〈0.05）.The treatment group maintenance rate of sinus rhythm was 56.8%（n=63）,the control group maintenance rate of sinus rhythm was 40.4%（n=40）,there was significant difference between two groups（P=0.018）.Treatment group and control group were compared：AF group compared with the sinus rhythm group hs-CRP,IL-6,Hcy concentrations increased significantly,the difference was statistically significant（P〈0.05）.Conclusion Rosuvastatin may decrease serum CRP,IL-6,Hcy concentrations by anti-inflammatory,inhibition of oxidative stress,improving myocardial fibrosis,thereby reduce the occurrence or recurrence of atrial fibrillation.
出处
《实用心脑肺血管病杂志》
2013年第6期40-43,共4页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
